Additional file 1 of Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results

Andreas R. Gantenbein, Reto Agosti, Christian P. Kamm, Gunther Landmann, Niklaus Meier, Gabriele Susanne Merki-Feld, Jens A. Petersen, Heiko Pohl, Philippe Ryvlin, Christoph J. Schankin, Dragana Viceic, Chiara Zecca, Elisabeth Schäfer, Ina Meyer & Michael E. Arzt
Additional file 1: Table S1. Common observed PPTFs by medication. Table S2. Reason for erenumab dose discontinuation/interruption before month 6.
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.